Prague Med. Rep. 2023, 124, 77-93
https://doi.org/10.14712/23362936.2023.7
Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection
References
1. , H. W., Shaltout, S. W., Sayed Ahmed, H. A., Fouad, A. M., Merrell, E., Riley, J. B., Salama, R., Abdelrahman, A. G., Darling, E., Fadel, G., Elfar, M. S. A., Sabry, K., Shah, J., Amin, H., Nieman, G. F., Mishriky, A., Aiash, H. (2021) Acetylsalicylic acid compared with enoxaparin for the prevention of thrombosis and mechanical ventilation in COVID-19 patients: A retrospective cohort study. Clin. Drug Investig. 41, 723–732.
<https://doi.org/10.1007/s40261-021-01061-2>
2. , M., Busman-Sahay, K., Vidal, S. J., Maliga, Z., Bondoc, S., Starke, C., Terry, M., Jacobson, C. A., Wrijil, L., Ducat, S., Brook, O. R., Miller, A. D., Porto, M., Pellegrini, K. L., Pino, M., Hoang, T. N., Chandrashekar, A., Patel, S., Stephenson, K., Bosinger, S. E., Andersen, H., Lewis, M. G., Hecht, J. L., Sorger, P. K., Martinot, A. J., Estes, J. D., Barouch, D. H. (2020) Vascular disease and thrombosis in SARS-CoV-2-infected rhesus macaques. Cell 183, 1354–1366.
<https://doi.org/10.1016/j.cell.2020.10.005>
3. , R., Vitrone, M., Ursi, M. P., Spiezia, S., Salemme, A., Florio, L. L., Boccia, F., Iossa, D., Zampino, R., Atripaldi, L., Squillante, F., Maturo, N., Fraganza, F., Severino, S., Punzi, R., Fiorentino, G. (2022) Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19. Blood Transfus. 20, 495–504.
4. , B., Mubarak, A., Hamed, M. E., Almutairi, A. Z., Alrashed, A. A., AlJuryyan, A., Enani, M., Alenzi, F. Q., Alturaiki, W. (2021) Complement anaphylatoxins and inflammatory cytokines as prognostic markers for COVID-19 severity and in-hospital mortality. Front. Immunol. 12, 668725.
<https://doi.org/10.3389/fimmu.2021.668725>
5. , H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C. T., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., Leaf, D. E., Kuter, D. J., Rosovsky, R. P. (2020) COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136, 489–500.
<https://doi.org/10.1182/blood.2020006520>
6. , U., Rittirsch, D., Flierl, M., Bruckner, U., Klos, A., Gebhard, F., Lambris, J. D., Huber-Lang, M. (2008) Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 632, 71–79.
7. , J., Mogg, R., Dunne, M. W., Bassyouni, M., David, C. V., Gonzalez, E., Rogalski-Salter, T., Shih, H., Silverman, J., Medema, J., Heaton, P. (2022) Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. Clin. Infect. Dis. 75, e473–e481.
<https://doi.org/10.1093/cid/ciab813>
8. , D., Heming, N., Grimaldi-Bensouda, L., Frémeaux-Bacchi, V., Vigan, M., Roux, A. L., Marchal, A., Michelon, H., Rottman, M., Moine, P. (2020) Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. EClinicalMedicine 28, 100590.
<https://doi.org/10.1016/j.eclinm.2020.100590>
9. , A., Iqbal, M. J., Mohammed, A., Alsaleh, A., Assiri, A., Noor, A., Nour, R., Khobrani, M. (2021) COVID-19 related treatment and outcomes among COVID-19 ICU patients: A retrospective cohort study. J. Infect. Public Health 14, 1274–1278.
<https://doi.org/10.1016/j.jiph.2021.08.030>
10. , W., Fattizzo, B., Giannotta, J. A., Quattrocchi, L., Aydin, S., Barone, F., Carbone, C., Pomponi, F., Metafuni, E., Beggiato, E., Sica, S., Di Bona, E., Lanza, F., Notaro, R., Iori, A. P. (2021) COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: An Italian multicentre survey. Br. J. Haematol. 194, 854–856.
<https://doi.org/10.1111/bjh.17558>
11. , S., Voci, D., Held, U., Sebastian, T., Bingisser, R., Colucci, G., Duerschmied, D., Frenk, A., Gerber, B., Götschi, A., Konstantinides, S. V., Mach, F., Robert-Ebadi, H., Rosemann, T., Simon, N. R., Spechbach, H., Spirk, D., Stortecky, S., Vaisnora, L., Righini, M., Kucher, N. (2022) Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): A randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol. 9, e585–e593.
<https://doi.org/10.1016/S2352-3026(22)00175-2>
12. , L., Lapidus, M. I., Martingano, I., Puga, M. C., Pollán, J. (2020) Neutrophil to lymphocyte ratio as a prognostic marker in COVID-19. Medicina (B. Aires) 80, 31–36 (Suppl. 3). (in Spanish)
13. , J. P., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., Capeau, J., Feve, B. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17, 4–12.
14. , S. S., O’Conner, S. D., Hulsebus, H. J., Ho, M. M., Fraser, D. A. (2014) Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front. Immunol. 5, 402.
<https://doi.org/10.3389/fimmu.2014.00402>
15. , L., Pithon-Curi, T. C., Curi, R., Hatanaka, E. (2020) COVID-19 and neutrophils: The relationship between hyperinflammation and neutrophil extracellular traps. Mediators Inflamm. 2020, 8829674.
<https://doi.org/10.1155/2020/8829674>
16. , G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., Agrusta, F., Bellizzi, A., Amitrano, M., Iannuzzo, M., Sacco, C., Lodigiani, C., Fontanella, A., Di Micco, P. (2021) Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: The FONDENOXAVID study. J. Blood Med. 12, 69–75.
<https://doi.org/10.2147/JBM.S285214>
17. , M., Kuppalli, K., Kindrachuk, J., Peiris, M. (2020) Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 371, m3862.
<https://doi.org/10.1136/bmj.m3862>
18. , A. J., Wiffen, L. J., Brown, T. P. (2020) COVID-19: A collision of complement, coagulation and inflammatory pathways. J. Thromb. Haemost. 18, 2110–2117.
<https://doi.org/10.1111/jth.14981>
19. , O. A., Sacramento, C. Q., Fintelman-Rodrigues, N., Temerozo, J. R., Pereira-Dutra, F., Mizurini, D. M., Monteiro, R. Q., Vazquez, L., Bozza, P. T., Castro-Faria-Neto, H. C., Souza, T. M. L. (2022) Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way. J. Mol. Cell Biol. 14, mjac039.
<https://doi.org/10.1093/jmcb/mjac039>
20. , E. A., Haghbayan, H. (2020) Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev. Med. Virol. 30, 1–9.
<https://doi.org/10.1002/rmv.2141>
21. , M., Meroni, P. L., Gualtierotti, R., Griffini, S., Grovetti, E., Torri, A., Lonati, P., Grossi, C., Borghi, M. O., Novembrino, C., Boscolo, M., Uceda Renteria, S. C., Valenti, L., Lamorte, G., Manunta, M., Prati, D., Pesenti, A., Blasi, F., Costantino, G., Gori, A., Bandera, A., Tedesco, F., Peyvandi, F. (2021) Complement activation and endothelial perturbation parallel COVID-19 severity and activity. J. Autoimmun. 116, 102560.
<https://doi.org/10.1016/j.jaut.2020.102560>
22. , A., Thomas, T., Dzieciatkowska, M., Hill, R. C., Francis, R. O., Hudson, K. E., Zimring, J. C., Hod, E. A., Spitalnik, S. L., Hansen, K. C. (2020) Serum proteomics in COVID-19 patients: Altered coagulation and complement status as a function of IL-6 level. J. Proteome Res. 19, 4417–4427.
<https://doi.org/10.1021/acs.jproteome.0c00365>
23. , R., Borges, M., Gonzalez-Freire, M. (2020) COVID-19: In the eye of the cytokine storm. Front. Immunol. 11, 558898.
<https://doi.org/10.3389/fimmu.2020.558898>
24. , S., Zhu, J., Jiang, J., Luo, X., Keshishian, A., Ferri, M., Rosenblatt, L., Schuler, P., Gutierrez, C., Dhamane, A. D. (2022) Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19. Curr. Med. Res. Opin. 38, 1891–1896.
<https://doi.org/10.1080/03007995.2022.2112871>
25. , F., Numis, F. G., Porta, G., Cirillo, F., Maddaluno, S., Ragozzino, A., De Negri, P., Di Gennaro, C., Pagano, A., Allegorico, E., Bressy, L., Bosso, G., Ferrara, A., Serra, C., Montisci, A., D’Amico, M., Schiano Lo Morello, S., Di Costanzo, G., Tucci, A. G., Marchetti, P., Di Vincenzo, U., Sorrentino, I., Casciotta, A., Fusco, M., Buonerba, C., Berretta, M., Ceccarelli, M., Nunnari, G., Diessa, Y., Cicala, S., Facchini, G. (2020) Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience. Eur. Rev. Med. Pharmacol. Sci. 24, 4040–4047.
26. , S. (2019) Complement and coagulation: Cross talk through time. Transfus. Med. Rev. 33, 199–206.
<https://doi.org/10.1016/j.tmrv.2019.08.004>
27. , O., Hultström, M., Persson, B., Lipcsey, M., Ekdahl, K. N., Nilsson, B., Frithiof, R. (2020) Mannose-binding lectin is associated with thrombosis and coagulopathy in critically ill COVID-19 patients. Thromb. Haemost. 120, 1720–1724.
28. , C. A., McLoughlin, R. M., McLeod, L., Colmont, C. S., Najdovska, M., Grail, D., Ernst, M., Jones, S. A., Topley, N., Jenkins, B. J. (2008) IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181, 2189–2195.
<https://doi.org/10.4049/jimmunol.181.3.2189>
29. , B., Peerschke, E. I. (2020) Complement and coagulation: Key triggers of COVID-19-induced multiorgan pathology. J. Clin. Invest. 130, 5674–5676.
<https://doi.org/10.1172/JCI142780>
30. , J., Hebert, C. A., Colbert, G. B. (2022) COVID-19-associated atypical hemolytic uremic syndrome and use of eculizumab therapy. J. Nephrol. 35, 317–321.
<https://doi.org/10.1007/s40620-021-01125-8>
31. , A., Humphreys, I. R. (2020) Elevated interleukin-6, interleukin-10 and neutrophil : lymphocyte ratio as identifiers of severe coronavirus disease 2019. Immunology 160, 221–222.
<https://doi.org/10.1111/imm.13225>
32. , J. E., Galindo-Coral, S., Montes, M. C., Muñoz Martin, A. J. (2021) Thrombosis and coagulopathy in COVID-19. Curr. Probl. Cardiol. 46, 100742.
<https://doi.org/10.1016/j.cpcardiol.2020.100742>
33. , F., Obermayer, A., Stoiber, W., Krautgartner, W. D., Steinbacher, P., Winterberg, N., Bathke, A. C., Klappacher, M., Studnicka, M. (2015) Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation. Respir. Res. 16, 59.
<https://doi.org/10.1186/s12931-015-0221-7>
34. , L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., Baric, R. S. (2018) Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9, e01753-18.
<https://doi.org/10.1128/mBio.01753-18>
35. , T., Kafri, Z., Al-Katib, A. (2021) Coagulation and anticoagulation in COVID-19. Blood Rev. 47, 100761.
<https://doi.org/10.1016/j.blre.2020.100761>
36. , T. L., Murray, B. P., Hagan, R. S., Mock, J. R. (2020) COVID-19: Clean up on IL-6. Am. J. Respir. Cell Mol. Biol. 63, 541–543.
<https://doi.org/10.1165/rcmb.2020-0277LE>
37. , A., Hakim, N., Barrientos, J. (2021) COVID-19 infection presenting as paroxysmal nocturnal hemoglobinuria. Clin. Case Rep. 9, e04636.
<https://doi.org/10.1002/ccr3.4636>
38. , A., Müller-Calleja, N., Pedrosa, D., Canisius, A., Sprinzl, M. F., Falter, T., Rossmann, H., Bodenstein, M., Werner, C., Sagoschen, I., Münzel, T., Schreiner, O., Sivanathan, V., Reuter, M., Niermann, J., Galle, P. R., Teyton, L., Ruf, W., Lackner, K. J. (2021) Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J. Thromb. Haemost. 19, 2335–2347.
<https://doi.org/10.1111/jth.15455>
39. , C., Perdomo, J., Calvo, A., Ferrando, C., Reverter, J. C., Tassies, D., Blasi, A. (2021) High D dimers and low global fibrinolysis coexist in COVID19 patients: What is going on in there? J. Thromb. Thrombolysis 51, 308–312.
<https://doi.org/10.1007/s11239-020-02226-0>
40. , Y., Li, J., Teng, Y., Sun, H., Tian, G., He, L., Li, P., Chen, Y., Guo, Y., Li, J., Zhao, G., Zhou, Y., Sun, S. (2019) Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV. Viruses 11, 39.
<https://doi.org/10.3390/v11010039>
41. , B., Gaspar-Chamu, A. D., Salgado-Jiménez, M. L. Á., Rodríguez-Echeverría, G. (2022) Enoxaparin dose associated with decreased risk of death in COVID-19. Rev. Med. Inst. Mex. Seguro Soc. 60, 33–39. (in Spanish)
42. , J., Chebotareva, N., Andreeva, E., Sorokin, Y., McDonnell, V., Stolyarevich, E., Moiseev, S. (2022) Thrombotic microangiopathy triggered by COVID-19: case reports. Nephron 146, 197–202.
<https://doi.org/10.1159/000520144>
43. , D., Kaimaparambil, V., Chandralekha, S., Lalchandani, J. (2022) Oral rivaroxaban in the prophylaxis of COVID-19 induced coagulopathy. J. Assoc. Physicians India 70, 11–12.
44. , C. J., French, Z., Kukulich, P., Lankiewicz, M., Ghimire, S., Maarouf, O. H., Rizk, S., Rhoades, R. (2021) Case series: Coronavirus disease 2019 infection as a precipitant of atypical hemolytic uremic syndrome: Two case reports. J. Med. Case Rep. 15, 587.
<https://doi.org/10.1186/s13256-021-03144-2>
45. , V. F., Imeraj, A., Gastoldi, S., Mele, C., Liguori, L., Condemi, C., Ruggenenti, P., Remuzzi, G., Carrara, C. (2022) Case report: Tackling complement hyperactivation with eculizumab in atypical hemolytic uremic syndrome triggered by COVID-19. Front. Pharmacol. 13, 842473.
<https://doi.org/10.3389/fphar.2022.842473>
46. , Q., Xie, Y., Cui, Z., Tang, S., Yuan, B., Huang, H., Hu, Y., Wang, Y., Zhou, M., Shi, C. (2020) Analysis of peripheral blood IL-6 and leukocyte characteristics in 364 COVID-19 patients of Wuhan. Front. Immunol. 11, 559716.
<https://doi.org/10.3389/fimmu.2020.559716>
47. , M. S., Mcrae, S. (2021) COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Crit. Rev. Oncol. Hematol. 168, 103529.
<https://doi.org/10.1016/j.critrevonc.2021.103529>
48. , Y., Du, X., Chen, J., Jin, Y., Peng, L., Wang, H. H. X., Luo, M., Chen, L., Zhao, Y. (2020) Neutrophil- to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J. Infect. 81, e6–e12.
49. , M. W., Kemper, C., Woodruff, T. M. (2020) COVID-19: Complement, coagulation, and collateral damage. J. Immunol. 205, 1488–1495.
<https://doi.org/10.4049/jimmunol.2000644>
50. , C., Mulvey, J. J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., Baxter-Stoltzfus, A., Laurence, J. (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl. Res. 220, 1–13.
<https://doi.org/10.1016/j.trsl.2020.04.007>
51. , C. M., Mulvey, J., Kubiak, J., Mikhail, S., Suster, D., Crowson, A. N., Laurence, J., Nuovo, G. (2021) Severe COVID-19: A multifaceted viral vasculopathy syndrome. Ann. Diagn. Pathol. 50, 151645.
<https://doi.org/10.1016/j.anndiagpath.2020.151645>
52. , I., Ciavarella, A., Abbattista, M., Aliberti, S., De Zan, V., Folli, C., Panigada, M., Gori, A., Artoni, A., Ierardi, A. M., Carrafiello, G., Monzani, V., Grasselli, G., Blasi, F., Peyvandi, F. (2021) Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern. Emerg. Med. 16, 1223–1229.
<https://doi.org/10.1007/s11739-020-02585-9>
53. , S., Ruggeri, A., Risitano, A. M., Angelillo, P., Yancopoulou, D., Mastellos, D. C., Huber-Lang, M., Piemontese, S., Assanelli, A., Garlanda, C., Lambris, J. D., Ciceri, F. (2020) The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin. Immunol. 215, 108450.
<https://doi.org/10.1016/j.clim.2020.108450>
54. , D. C., Pires da Silva, B. G. P., Fonseca, B. A. L., Fonseca, N. P., Auxiliadora-Martins, M., Mastaglio, S., Ruggeri, A., Sironi, M., Radermacher, P., Chrysanthopoulou, A., Skendros, P., Ritis, K., Manfra, I., Iacobelli, S., Huber-Lang, M., Nilsson, B., Yancopoulou, D., Connolly, E. S., Garlanda, C., Ciceri, F., Risitano, A. M., Calado, R. T., Lambris, J. D. (2020) Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin. Immunol. 220, 108598.
<https://doi.org/10.1016/j.clim.2020.108598>
55. , S. W., Mathe, A., Bruce, J., Liu, G., Maltby, S., Fricker, M., Goggins, B. J., Tay, H. L., Marks, E., Burns, G., Kim, R. Y., Minahan, K., Walker, M. M., Callister, R. C., Foster, P. S., Horvat, J. C., Hansbro, P. M., Keely, S. (2018) IL-6 drives neutrophil-mediated pulmonary inflammation associated with bacteremia in murine models of colitis. Am. J. Pathol. 188, 1625–1639.
<https://doi.org/10.1016/j.ajpath.2018.03.016>
56. , A. C., Monteleone, J. P. R., Kazani, S. D., Ortiz, S. R. (2021) Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe coronavirus disease 2019. Infect. Dis. Ther. 10, 1045–1054.
<https://doi.org/10.1007/s40121-021-00425-7>
57. , C. B., Demichev, V., Wendisch, D., Michalick, L., White, M., Freiwald, A., Textoris-Taube, K., Vernardis, S. I., Egger, A. S., Kreidl, M., Ludwig, D., Kilian, C., Agostini, F., Zelezniak, A., Thibeault, C., Pfeiffer, M., Hippenstiel, S., Hocke, A., von Kalle, C., Campbell, A., Hayward, C., Porteous, D. J., Marioni, R. E., Langenberg, C., Lilley, K. S., Kuebler, W. M., Mülleder, M., Drosten, C., Suttorp, N., Witzenrath, M., Kurth, F., Sander, L. E., Ralser, M. (2020) Ultra-high-throughput clinical proteomics reveals classifiers of COVID-19 infection. Cell Syst. 11, 11-24.e4.
<https://doi.org/10.1016/j.cels.2020.05.012>
58. , A. S., Ahmad, H. M., Abdul-Raheem, A. S. A., Kamel, F. M. M., Khames, A., Mady, A. F. (2022) Thromboprophylaxis and clinical outcomes in moderate COVID-19 patients: A comparative study. Res. Social Adm. Pharm. 18, 4048–4055.
<https://doi.org/10.1016/j.sapharm.2022.07.004>
59. , N., Podda, G., Birocchi, S., Bonacchini, L., Merli, M., Trezzi, M., Massaini, G., Agostinis, M., Carioti, G., Saverio Serino, F., Gazzaniga, G., Barberis, D., Antolini, L., Grazia Valsecchi, M., Cattaneo, M. (2022) Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 randomized trial. Eur. J. Clin. Invest. 52, e13735.
<https://doi.org/10.1111/eci.13735>
60. , K. A., Shishkova, E., Miller, I. J., Balnis, J., Bernstein, M. N., Peters-Clarke, T. M., Meyer, J. G., Quan, Q., Muehlbauer, L. K., Trujillo, E. A., He, Y., Chopra, A., Chieng, H. C., Tiwari, A., Judson, M. A., Paulson, B., Brademan, D. R., Zhu, Y., Serrano, L. R., Linke, V., Drake, L. A., Adam, A. P., Schwartz, B. S., Singer, H. A., Swanson, S., Mosher, D. F., Stewart, R., Coon, J. J., Jaitovich, A. (2021) Large-scale multi-omic analysis of COVID-19 severity. Cell Syst. 12, 23-40.e7.
<https://doi.org/10.1016/j.cels.2020.10.003>
61. , L., Fossali, T., Frangipane, V., Bozzini, S., Morosini, M., D’Amato, M., Lettieri, S., Urtis, M., Di Toro, A., Saracino, L., Percivalle, E., Tomaselli, S., Cavagna, L., Cova, E., Mojoli, F., Bergomi, P., Ottolina, D., Lilleri, D., Corsico, A. G., Arbustini, E., Colombo, R., Meloni, F. (2020) Broncho-alveolar inflammation in COVID-19 patients: A correlation with clinical outcome. BMC Pulm. Med. 20, 301.
<https://doi.org/10.1186/s12890-020-01343-z>
62. , C., Venkatakrishnan, A. J., Kirkup, C., Berner, G., Puranik, A., O’Horo, J. C., Badley, A. D., Soundararajan, V. (2021) Enoxaparin is associated with lower rates of mortality than unfractionated heparin in hospitalized COVID-19 patients. EClinicalMedicine 33, 100774.
<https://doi.org/10.1016/j.eclinm.2021.100774>
63. , X., Kong, H., Ding, W., Wu, C., Ji, N., Huang, M., Li, T., Wang, X., Wen, J., Wu, W., Wu, M., Huang, C., Li, Y., Liu, Y., Tang, J. (2021) Abnormal coagulation function of patients with COVID-19 is significantly related to hypocalcemia and severe inflammation. Front. Med. (Lausanne) 8, 638194.
<https://doi.org/10.3389/fmed.2021.638194>
64. , E., Barile Agati, L., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., de Oliveira, C. C. C., Lins Dos Santos, J., Volpiani, G. G., Sobreira, M. L., Joviliano, E. E., Bohatch Júnior, M. S., da Fonseca, B. A. L., Ribeiro, M. S., Dusilek, C., Itinose, K., Sanches, S. M. V., de Almeida Araujo Ramos, K., de Moraes, N. F., Tierno, P. F. G. M. M., de Oliveira, A. L. M. L., Tachibana, A., Chate, R. C., Santos, M. V. B., de Menezes Cavalcante, B. B., Moreira, R. C. R., Chang, C., Tafur, A., Fareed, J., Lopes, R. D. (2022) Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): An open-label, multicentre, randomised, controlled trial. Lancet 399(10319), 50–59.
<https://doi.org/10.1016/S0140-6736(21)02392-8>
65. , P., Talasaz, A. H., Rashidi, F., Sharif-Kashani, B., Beigmohammadi, M. T., Farrokhpour, M., Sezavar, S. H., Payandemehr, P., Dabbagh, A., Moghadam, K. G., Jamalkhani, S., Khalili, H., Yadollahzadeh, M., Riahi, T., Rezaeifar, P., Tahamtan, O., Matin, S., Abedini, A., Lookzadeh, S., Rahmani, H., Zoghi, E., Mohammadi, K., Sadeghipour, P., Abri, H., Tabrizi, S., Mousavian, S. M., Shahmirzaei, S., Bakhshandeh, H., Amin, A., Rafiee, F., Baghizadeh, E., Mohebbi, B., Parhizgar, S. E., Aliannejad, R., Eslami, V., Kashefizadeh, A., Kakavand, H., Hosseini, S. H., Shafaghi, S., Ghazi, S. F., Najafi, A., Jimenez, D., Gupta, A., Madhavan, M. V., Sethi, S. S., Parikh, S. A., Monreal, M., Hadavand, N., Hajighasemi, A., Maleki, M., Sadeghian, S., Piazza, G., Kirtane, A. J., Van Tassell, B. W., Dobesh, P. P., Stone, G. W., Lip, G. Y. H., Krumholz, H. M., Goldhaber, S. Z., Bikdeli, B. (2021) Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. JAMA 325, 1620–1630.
66. , P., Mitsios, A., Chrysanthopoulou, A., Mastellos, D. C., Metallidis, S., Rafailidis, P., Ntinopoulou, M., Sertaridou, E., Tsironidou, V., Tsigalou, C., Tektonidou, M., Konstantinidis, T., Papagoras, C., Mitroulis, I., Germanidis, G., Lambris, J. D., Ritis, K. (2020) Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 130, 6151–6157.
<https://doi.org/10.1172/JCI141374>
67. , K., Nagaharu, K., Hachiya, K., Nishimura, K., Matsumoto, T., Tawara, I. (2022) A hemolytic episode following COVID-19 in a case with atypical hemolytic uremic syndrome. Rinsho Ketsueki 63, 224–228.
68. , D., Taghavi, S., Houghton, A., Stover, J., Toraih, E., Duchesne, J. (2020) Neutrophil-to-lymphocyte ratio and outcomes in Louisiana COVID-19 patients. Shock 54, 652–658.
<https://doi.org/10.1097/SHK.0000000000001585>
69. , D. (2012) Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv. Clin. Exp. Med. 21, 105–114.
70. , M. W. (2003) The role of mannose-binding lectin in health and disease. Mol. Immunol. 40, 423–429.
<https://doi.org/10.1016/S0161-5890(03)00155-X>
71. , F. P., Pontelli, M. C., Silva, C. M., Toller-Kawahisa, J. E., de Lima, M., Nascimento, D. C., Schneider, A. H., Caetité, D., Tavares, L. A., Paiva, I. M., Rosales, R., Colón, D., Martins, R., Castro, I. A., Almeida, G. M., Lopes, M. I. F., Benatti, M. N., Bonjorno, L. P., Giannini, M. C., Luppino-Assad, R., Almeida, S. L., Vilar, F., Santana, R., Bollela, V. R., Auxiliadora-Martins, M., Borges, M., Miranda, C. H., Pazin-Filho, A., da Silva, L. L. P., Cunha, L. D., Zamboni, D. S., Dal-Pizzol, F., Leiria, L. O., Siyuan, L., Batah, S., Fabro, A., Mauad, T., Dolhnikoff, M., Duarte-Neto, A., Saldiva, P., Cunha, T. M., Alves-Filho, J. C., Arruda, E., Louzada-Junior, P., Oliveira, R. D., Cunha, F. Q. (2020) SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 217, e20201129.
<https://doi.org/10.1084/jem.20201129>
72. , G., Hao, S., Fu, C., Hu, W., Xie, L., Wu, Q., Li, S., Liu, X. (2021) The effect of coagulation factors in 2019 novel coronavirus patients: A systematic review and meta-analysis. Medicine (Baltimore) 100, e24537.
<https://doi.org/10.1097/MD.0000000000024537>
73. , M., Zhang, Y., Zhang, S., Qin, X., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., Wang, C., Zhao, J., Sun, X., Tian, R., Wu, W., Wu, D., Ma, J., Chen, Y., Zhang, D., Xie, J., Yan, X., Zhou, X., Liu, Z., Wang, J., Du, B., Qin, Y., Gao, P., Lu, M., Hou, X., Wu, X., Zhu, H., Xu, Y., Zhang, W., Li, T., Zhang, F., Zhao, Y., Li, Y., Zhang, S. (2020) Antiphospholipid antibodies in critically ill patients with COVID-19. Arthritis Rheumatol. 72, 1998–2004.
<https://doi.org/10.1002/art.41425>
74. , S., Wiwanitkit, V. (2020) COVID-19, antiphospholipid syndrome and thrombosis. Clin. Appl. Thromb. Hemost. 26, 1076029620931927.
<https://doi.org/10.1177/1076029620931927>
75. , Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., Wang, C., Zhao, J., Sun, X., Tian, R., Wu, W., Wu, D., Ma, J., Chen, Y., Zhang, D., Xie, J., Yan, X., Zhou, X., Liu, Z., Wang, J., Du, B., Qin, Y., Gao, P., Qin, X., Xu, Y., Zhang, W., Li, T., Zhang, F., Zhao, Y., Li, Y., Zhang, S. (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 382, e38.
<https://doi.org/10.1056/NEJMc2007575>
